UK Markets close in 4 hrs 35 mins

Primary Sclerosing Cholangitis (PSC) Market Landscape 2021-2031

·2-min read

Dublin, Dec. 23, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Primary Sclerosing Cholangitis (PSC)" report has been added to's offering.

This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) industry, comprising key pipeline drugs, recent events and analyst opinion, upcoming events, clinical trials, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast.

Key Takeaways

  • The publisher estimates that in 2019, there were 241,800 prevalent cases of primary sclerosing cholangitis (PSC) worldwide among adults aged 30 years and over, and forecasts that number to increase to 277,300 prevalent cases by 2028.

  • The majority of industry-sponsored drugs in active clinical development for PSC are in Phase II, with just a single product in Phase III.

  • Therapies in the pipeline for PSC focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route, with one product being tested in an intravenous formulation.

  • The only high-impact upcoming event for drugs in the PSC space is topline Phase II trial results for HTD1801. The overall likelihood of approval of a Phase I autoimmune/immunology-other asset is 19.2%, and the average probability a drug advances from Phase III is 67.3%. Drugs, on average, take 10 years from Phase I to approval, compared to 9.4 years in the overall autoimmune/immunology space.

  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PSC have been in the early and midphases of development, with 85% of trials in Phase I-II, and only 15% in Phase III.

  • The US leads in terms of the number of PSC clinical trials globally, while the UK leads the major European markets.

  • Gilead Sciences has three completed trials and two ongoing trials in PSC.

  • Gilead Sciences and Takeda are the only companies to have conducted Phase III trials for PSC.

Key Topics Covered


Key Takeaways

Disease Background

  • Subtypes



Pipeline Drugs

Recent Events and Analyst Opinion

  • Seladelpar for PSC (November 25, 2019)

Key Upcoming Events

Probability of Success

Clinical Trial Landscape

  • Sponsors by status

  • Sponsors by phase



For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting